ArriVent BioPharma (AVBP) Net Cash Flow (2023 - 2026)
ArriVent BioPharma (AVBP) posted Net Cash Flow of $16.6 million for Q1 2026, up 124.67% sequentially from -$67.1 million in Q4 2025, and up 167.8% YoY from $6.2 million in Q1 2025.
ArriVent BioPharma (AVBP) Net Cash Flow (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Net Cash Flow for 4 years, with the latest figure at $16.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 167.8% year-over-year to $16.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (up 116.3% YoY) and the FY2025 annual result came in at -$28.8 million, up 62.21% from the prior year.
- Net Cash Flow climbed to $16.6 million in Q1 2026 per AVBP's latest filing, from -$67.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $167.0 million in Q1 2024 and troughed at -$67.1 million in Q4 2025.
- A 4-year average of $7.0 million and a median of -$15.8 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 494.57% in 2024, then tumbled 317.05% in 2025.
- Over 4 years, Net Cash Flow stood at -$16.0 million in 2023, then fell by 0.8% to -$16.1 million in 2024, then sank by 317.05% to -$67.1 million in 2025, then soared by 124.67% to $16.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $16.6 million, -$67.1 million, and -$93000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 92.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.58 Mn |
| Jun 30, 2026 | 92.58 Mn |
| Mar 31, 2026 | 16.56 Mn |
| Mar 31, 2026 | 16.56 Mn |
| Dec 31, 2025 | -67.13 Mn |
| Dec 31, 2025 | -67.13 Mn |
| Sep 30, 2025 | -93,000.00 |
| Sep 30, 2025 | -93,000.00 |
| Jun 30, 2025 | 62.90 Mn |
| Jun 30, 2025 | 62.90 Mn |
| Mar 31, 2025 | -24.43 Mn |
| Mar 31, 2025 | -24.43 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Sep 30, 2024 | -15.81 Mn |
| Sep 30, 2024 | -15.81 Mn |
| Jun 30, 2024 | -18.72 Mn |
| Jun 30, 2024 | -18.72 Mn |
| Mar 31, 2024 | 167.00 Mn |
| Mar 31, 2024 | 167.00 Mn |